The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

Selvita to Host Conference Call and Webcast on Thursday,…

Krakow, Poland – 21 March 2019 – Selvita (WSE:SLV), a clinical stage company engaged in the research and development of...
More

Selvita Appoints Chief Medical Officer Steffen Heeger, M.D., MSc.,…

Krakow, Poland – 15 March 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the...
More

Selvita to Exhibit at the 3rd Annual Drug Discovery…

Krakow, Poland – 11 March 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, today...
More

Selvita to Present Data from Multiple Oncology Programs at…

Krakow, Poland – 4 March 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the...
More

Selvita Analytical Laboratory GMP Certifications will be automatically recognized…

Krakow, Poland – 15 February 2019 - Selvita, one of the largest drug discovery companies in Europe, announced that Selvita...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

Research and Development

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.


The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

More

Investor Relations SLV 0,8000 PLN ( 1,46% )

Share price 2019-03-22 17:00:00

55,6000 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More